Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page's revision tag changed from v3.5.3 to v3.5.4, indicating a minor platform update. There is no evidence of changes to the study details or other content on the page.
    Difference
    0.1%
    Check dated 2026-05-15T03:14:37.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A bibliographic citation was added referencing the 2012 NEJM article 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.' This background reference situates the trial within the broader PD-L1 inhibitor literature.
    Difference
    0.1%
    Check dated 2026-05-07T23:13:02.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision updated from v3.5.2 to v3.5.3, signaling a new release of the page content. This update represents a metadata/version change rather than substantive changes to the study details.
    Difference
    0.1%
    Check dated 2026-04-30T17:33:09.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed an older NEJM trial citation from the page; no substantive study details, eligibility criteria, or outcomes were altered.
    Difference
    0.1%
    Check dated 2026-04-16T10:30:29.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 at the top of the page. This is a minor version update that does not alter study details.
    Difference
    0.1%
    Check dated 2026-03-25T20:52:09.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The visible study content and layout remain unchanged.
    Difference
    0.1%
    Check dated 2026-03-11T17:28:18.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.